701 related articles for article (PubMed ID: 25175794)
1. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
Pasvolsky O; Bassett RL; Ghanem S; Cuglievan B; Tewari P; Hosing C; Srour S; Ramdial J; Mahadeo KM; Khazal S; Petropoulos D; Popat U; Qazilbash M; Kebriaei P; Champlin R; Shpall EJ; Nieto Y
BMC Cancer; 2023 Dec; 23(1):1258. PubMed ID: 38124057
[TBL] [Abstract][Full Text] [Related]
4. CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma.
Berger MD; Branger G; Leibundgut K; Baerlocher GM; Seipel K; Mueller BU; Gregor M; Ruefer A; Pabst T
Leuk Res; 2015 Jun; 39(6):561-7. PubMed ID: 25890431
[TBL] [Abstract][Full Text] [Related]
5. Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas.
Wu M; Wang X; Xie Y; Liu W; Zhang C; Ping L; Ying Z; Deng L; Zheng W; Lin N; Tu M; Song Y; Zhu J
Int J Med Sci; 2018; 15(9):867-874. PubMed ID: 30008598
[No Abstract] [Full Text] [Related]
6. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
[TBL] [Abstract][Full Text] [Related]
7. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Schorb E; Fox CP; Fritsch K; Isbell L; Neubauer A; Tzalavras A; Witherall R; Choquet S; Kuittinen O; De-Silva D; Cwynarski K; Houillier C; Hoang-Xuan K; Touitou V; Cassoux N; Marolleau JP; Tamburini J; Houot R; Delwail V; Illerhaus G; Soussain C; Kasenda B
Bone Marrow Transplant; 2017 Aug; 52(8):1113-1119. PubMed ID: 28436974
[TBL] [Abstract][Full Text] [Related]
8. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
9. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Chow VA; Rajendran JG; Fisher DR; Appelbaum FR; Cassaday RD; Martin PS; Holmberg LA; Gooley TA; Stevenson PA; Pagel JM; Green DJ; Press OW; Gopal AK
Am J Hematol; 2020 Jul; 95(7):775-783. PubMed ID: 32243637
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
[TBL] [Abstract][Full Text] [Related]
16. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
Inano S; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Arima N
Int J Hematol; 2014 Feb; 99(2):162-8. PubMed ID: 24338743
[TBL] [Abstract][Full Text] [Related]
17. Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma.
Puckrin R; Sterrett R; Shafey M; Chua N; Stewart D
Transplant Cell Ther; 2022 Nov; 28(11):762.e1-762.e4. PubMed ID: 36058549
[TBL] [Abstract][Full Text] [Related]
18. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
